Asset
CRETOSTIMOGENE GRENADENOREPVEC
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06111235 | phase3 | active_not_recruiting | 2023-12-14 | 2026-11-01 | CG Oncology, Inc. | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
| NCT06567743 | phase2 | recruiting | 2024-09-16 | 2027-03-31 | CG Oncology, Inc. | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
| NCT02365818 | phase2 | completed | 2015-06-02 | 2018-08-01 | CG Oncology, Inc. | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure |
| NCT04387461 | phase2 | completed | 2020-12-08 | 2023-03-07 | CG Oncology, Inc. | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin |
| NCT04452591 | phase3 | active_not_recruiting | 2020-10-27 | 2030-06-16 | CG Oncology, Inc. | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin |
FDA applications (0)
This company has no applications containing this asset.